Press releases

2021  |  2020  |  2019  |  2018  |  All
March 5, 2021
Compass Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 4, 2021
Compass Therapeutics Announces Participation in March 2021 Investor Conferences
March 4, 2021
Compass Therapeutics to Commence Trading on the OTCQB Venture Market Under the Symbol “CMPX”

Presentations and publications

View all
March 12, 2020 | JCI Insight
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity
November 12, 2019 | SITC 2019
CTX-8371, a Novel Bispecific Targeting both PD-1 and PD-L1, is more Potent than Combination anti-PD-1 and PD-L1 Therapy and Provides Enhanced Protection from Tumors in vivo
November 12, 2019 | SITC 2019
A novel class of Innate Cell Engagers targeting NKp30

In the news

View all
September 17, 2020
Checkpoint Inhibitor CTX-2026 Shows Promising Efficacy in Preclinical Study
August 20, 2020
Ayala Pharmaceuticals Announces the Appointment of Vered Bisker-Leib, Ph.D. To Its Board of Directors
April 6, 2020
Compass Therapeutics’ immuno-oncology prospect clears solid tumors in mice